インデックス付き
- Jゲートを開く
- アカデミックキー
- 研究聖書
- 中国国家知識基盤 (CNKI)
- 国際農業生物科学センター (CABI)
- レフシーク
- ハムダード大学
- エブスコ アリゾナ州
- OCLC-WorldCat
- CABI全文
- パブロン
- ジュネーブ医学教育研究財団
- Google スカラー
このページをシェアする
ジャーナルチラシ
概要
Sickle Cell Disease (SCD) and COVID-19: Case Series
Awaji Q. Al-Naami, Liaqat A. Khan, Faisal I. Zaidan, Hussam M.Halawi, Laila E.Asiri, Taher A.Suamili, Amal A. Qaisi, Turki M.Darweesh, Ibrahim A Al-Naami
The ongoing pandemic of COVID-19 that started in the Hubei province of China in late December 2019, caused by severe acute respiratory syndrome corona virus-2 (SARS CoV-2). Globally millions affected by the disease so far. The risk of COVID-19 severity and its complications increases with age and other comorbidities. The course of SARS-CoV-2 infection or its related complications has yet to be established in patients with sickle cell disease (SCD), once more evidence is available. It is clear from the available data that the course of COVID-19 in patients with SCD is mild to moderate, seldom severe, and rarely fatal. Herein we report three known cases of SCD with confirmed COVID-19, in whom the course of the disease was mild to moderate and uncomplicated with uneventful recoveries.